Energy is indispensable for all biological processes across organisms. The primary mechanism by which cells produce energy is through oxidative phosphorylation (OXPHOS)¹. This important metabolic pathway utilizes energy derived from a series of oxidation–reduction reactions to synthesize adenosine triphosphate (ATP), the principal molecule used to store and transfer energy in cells. These redox reactions involve electron transfer between molecules, resulting in changes in their oxidation states.

During OXPHOS, electron carriers such as nicotinamide adenosine diphosphate (NADH) and flavin adenine dinucleotide (FADH₂)—produced in metabolic pathways such as glycolysis, fatty acid oxidation, and the citric acid cycle (Krebs cycle)—donate electrons after being oxidized. These electrons traverse the electron transport chain (ETC), where molecules such as ubiquinone and cytochrome c facilitate electron transport. Ultimately, electrons combine with oxygen to form water.

In 1961, Peter Mitchell introduced the chemiosmotic hypothesis, which transformed our understanding of ATP synthesis². This theory posits that the ETC generates a proton gradient, which powers ATP synthase to produce ATP. The gradient, called the proton-motive force (PMF), is composed of both a pH gradient and an electric potential. Although initially controversial, Mitchell’s hypothesis gained widespread acceptance and earned him the Nobel Prize in Chemistry in 1978.

This article delves into the location, mechanisms, regulation, and significance of OXPHOS in energy production within the cell.

Cellular location of oxidative phosphorylation

The process of OXPHOS occurs in both prokaryotic and eukaryotic cells; however, the specific cellular locations differ.

Eukaryotes

In eukaryotes, mitochondria are the primary site for ATP production via OXPHOS¹. The mitochondrion has two membranes: the outer membrane and the inner membrane, the latter of which is highly folded into structures called cristae, increasing the surface area for energy production.

The inner mitochondrial membrane contains ETC complexes and encloses the matrix, which holds mitochondrial DNA, ribosomes, and essential enzymes. The cristae contain OXPHOS complexes (I–IV), namely NADH-ubiquinone oxidoreductase, succinate dehydrogenase, ubiquinol-cytochrome c oxidoreductase, cytochrome c oxidase, and ATP synthase (complex V)³. Complexes I–IV create an electrochemical proton gradient. Electrons travel through these complexes, which are ultimately used by the ATP synthase to synthesize ATP.

The intermembrane space accumulates hydrogen ions, creating a proton gradient that generates a membrane potential for ATP synthesis.

Prokaryotes

In prokaryotes, which lack mitochondria, oxidative phosphorylation occurs at the plasma membrane⁴. The ETC components are embedded in the inner plasma membrane, and electron transfer takes place along this membrane, generating a proton gradient. This gradient, in turn, drives ATP synthesis in a manner analogous to eukaryotes.

Steps involved in oxidative phosphorylation

OXPHOS is composed of two primary components: the ETC and chemiosmosis^{1, 5}.

Step 1: Electron transfer through the ETC

To appreciate OXPHOS at the molecular level, it is important to understand the protein complexes involved in this process.

1. Complex I (NADH dehydrogenase) is the largest enzyme within the ETC. It features an “L”-shaped conformation, partially embedded within the inner mitochondrial membrane and extending into the mitochondrial matrix. The matrix-facing arm facilitates electron transfer from NADH to ubiquinone (Coenzyme Q) through a flavin mononucleotide (FMN) and a series of seven iron–sulfur clusters, effectively reducing ubiquinone and promoting electron flow. Simultaneously, the membrane-embedded arm functions as a proton pump, translocating protons across the inner mitochondrial membrane³. The matrix arm consists of seven core subunits, organized into the N-module, which houses the NADH binding site, and the Q-module, responsible for ubiquinone reduction. The membrane arm is divided into proximal and distal proton pump modules. Electron transfer coupled with ubiquinone reduction induces conformational changes that drive the movement of four protons through distinct channels across the membrane.
2. Complex II (succinate dehydrogenase) is an alternative entry point for electrons into the respiratory chain. It consists of four subunits, A–D, with one hydrophilic domain, made of the subunits A and B, protruding into the mitochondrial matrix. The two other subunits, C and D, anchor the complex to the mitochondrial inner membrane. It oxidizes FADH₂ and transfers electrons to ubiquinone via iron–sulfur clusters. Unlike other complexes, it does not function as a proton pump and does not contribute to the proton gradient.
3. Complex III (cytochrome c oxidoreductase) functions as a dimer in the membrane and oxidizes ubiquinol to ubiquinone, pumping two protons into the intermembrane space. It transfers electrons from ubiquinol to cytochrome c through cytochromes b and c1. This process contributes to the proton gradient needed for ATP synthesis.
4. Complex IV (cytochrome c oxidase) is the final enzyme in the mitochondrial ETC. It transfers electrons from cytochrome c to oxygen via hemes and a copper atom, forming water molecules. During this process, four protons are pumped into the intermembrane space, contributing to the proton gradient. Structural data have established that plant complex IV contains 10 subunits, compared to 12 in yeast, and 13 in mammals³.
5. Step 2: Proton gradient formation (chemiosmosis)

Chemiosmosis combines electron transport with ATP synthesis by using the energy stored in a proton gradient across biological membranes. This process involves the following key steps:

• As electrons pass through complexes I, III, and IV in the ETC, protons are actively pumped from the mitochondrial matrix into the intermembrane space, creating a proton gradient. A total of 10 protons from the oxidation of NADH and 6 protons from the oxidation of FADH₂ are formed in the intermembrane space.
• This gradient creates a pH difference (matrix pH ~8 vs intermembrane space pH ~7) and an electric potential (~0.14 V), with the matrix being negative.
• The energy stored in this electrochemical gradient drives protons back into the matrix through ATP synthase, facilitating ATP production. This mechanism is a fundamental process in mitochondria, chloroplasts, and bacteria for energy generation.

Step 3: ATP synthesis by ATP synthase

The inner mitochondrial membrane’s phospholipid bilayer is impermeable to protons; therefore, protons cross only through ATP synthase (Complex V). ATP synthase uses the energy from the electrochemical proton gradient to convert ADP and inorganic phosphate into ATP. It consists of two main parts:

1. The water-soluble F1 portion catalyzes ATP synthesis. It contains eight subunits: three alpha (α), three beta (β), gamma (γ), delta (δ), and epsilon (ε). The γ, δ, and ε subunits form the central stalk or rotor shaft. The α and β subunits form a hexameric ring where ATP synthesis occurs via the binding change mechanism. The γ subunit protrudes into the ring and interacts with ε, connecting to the F0 portion. The αβ ring remains fixed and drives catalysis.
2. The membrane-embedded F0 portion forms the proton channel that drives the rotation of the c-ring and central stalk. Bacterial F0 is simpler, composed of a1, b2, and 10–14 c subunits. Eukaryotic F0 contains additional subunits (d, F6, OSCP) that form the peripheral stalk, stabilizing the stators (F1 αβ3 and F0 a) and preventing their rotation with the rotor (γ, δ, ε, and F0 c). Other subunits (e, f, g, and A6L) extend across the membrane with F0.

ATP synthesis follows the binding change mechanism, proposed by Paul Boyer, which relies on rotation induced by proton flow through F0⁶. Proton passage causes the c-ring and attached γ subunit to rotate within the α3β3 hexamer, which is held stationary by the peripheral stalk. The γ subunit sequentially interacts with each β subunit, cycling them through three conformations: βT (ATP-bound), βD (ADP-bound), and βE (empty).

Each 120° rotation of γ forces a β subunit into the βE conformation, and the others adopt βD and βT. One full rotation cycles all three β subunits through these states, producing three ATP molecules.

Thus, synthesizing one ATP requires the movement of four protons through F0. Because complexes I, III, and IV pump protons, one NADH oxidation yields 2.5-3 ATP, whereas FADH₂ oxidation produces 1.5-2 ATP, as it bypasses Complex I and pumps fewer protons.

F1-ATPase synthesizes ATP from ADP and Pi when rotated clockwise at about five ATP molecules per second⁶.

Key reactants and products of oxidative phosphorylation

Key reactants include:

• NADH and FADH₂: These electron carriers are generated during previous stages of cellular respiration, including glycolysis and the citric acid cycle. They donate electrons to the ETC to initiate OXPHOS.
• Oxygen (O₂): Oxygen serves as the terminal electron acceptor in the ETC. It combines with electrons and protons to form water.
• ADP and Inorganic Phosphate (Pi): These substrates are required for the synthesis of ATP by ATP synthase.

The OXPHOS products include:

• ATP: The primary energy currency formed as a product that drives other physiological and cellular activities, such as transporting ions and initiating cell communication.
• Water (H₂O): Formed when molecular oxygen accepts electrons at the end of the ETC and splits into two.
• NAD⁺ and FAD: The oxidized forms of NADH and FADH₂, which are recycled and used in earlier stages of cellular respiration⁷.

Energy production

OXPHOS is responsible for producing the majority of ATP in cells. During glycolysis, 2 NADH and 2 ATP molecules are produced. Pyruvate oxidation generates 2 NADH, and the citric acid cycle produces 6 NADH, 2 FADH₂, and 2 ATP. The oxidation of 10 NADH molecules contributes approximately 25 ATP, and the oxidation of 2 FADH₂ produces approximately 3 ATP, yielding a total of 30-32 ATP molecules per glucose molecule.

Regulation and efficiency of oxidative phosphorylation

The regulation of OXPHOS is influenced by factors such as substrate availability, ATP demand, and feedback inhibition by ATP and NADH. The efficiency of OXPHOS is also affected by factors such as proton leakage and the presence of uncoupling proteins.

Substrate availability

The efficiency and kinetics of mitochondrial OXPHOS vary based on the choice of respiratory substrates⁹. For example, mitochondria in heart tissue, which has a higher energy demand, exhibit higher respiratory rates and OXPHOS efficiencies than mitochondria in the kidney. The availability of ADP also plays a crucial role in regulating ATP production. Low ADP concentrations slow down the ETC and ATP synthesis.

Further, the concentration of ADP is a limiting factor¹⁰. Low ADP levels can slow down the ETC and ATP synthesis. In most cells, ATP and Pi concentrations are much higher than ADP, making ADP the key regulator of energy state changes. ATP synthesis remains low until ADP reaches around 30 μM, after which it rapidly increases.

Feedback inhibition: ATP inhibits Complex IV activity

Excess ATP can inhibit the activity of Complex IV via allosteric feedback, preventing excessive ATP production¹¹. This mechanism helps maintain energy balance and minimizes the generation of reactive oxygen species (ROS), a reaction that comprises allosteric ATP-inhibition of cytochrome c oxidase. For example, the bovine heart enzyme has 10 high-affinity ADP binding sites, with ATP replacing ADP at high ATP/ADP ratios, leading to sigmoidal inhibition of oxygen uptake kinetics. This inhibition suggests cooperativity between two ferrocytochrome c-binding sites, requiring a dimeric cytochrome oxidase structure for ATP-mediated allosteric regulation.

Oxygen availability in tissues

Oxygen is essential for the ETC, and hypoxic conditions can disrupt oxidative phosphorylation¹². A study has indicated that glucocorticoids decrease oxygen bioavailability at the inner mitochondrial membrane, inhibiting Complex V and affecting OXPHOS¹³.

For example, in the tumor microenvironment, low oxygen conditions often prevail owing to inadequate blood supply¹⁴. This hypoxic condition induces the primary lesions in the cancer cells to shift from OXPHOS to anaerobic glycolysis, a phenomenon known as the Warburg effect. This results in increased lactate production. The accumulated lactate contributes to tumor progression by promoting angiogenesis, immune evasion, and metastasis.

Importance of oxidative phosphorylation in cellular metabolism

OXPHOS generates about 90% of the ATP needed for fulfilling high energy demands in higher animals and plants¹⁵. It plays a crucial role in sustaining life by powering cellular activities.

Anaerobic processes, including fermentation and lactate production, which occur after glycolysis, are much less efficient in ATP production compared to aerobic processes. Glycolysis alone produces a net gain of only 2 ATP molecules per glucose molecule. This process helps to regulate and maintain metabolic homeostasis. It can generate approximately 15 times more ATP from the same amount of glucose¹⁵.

The ATP produced during the process of OXPHOS aids in several functions.

• Active transport: It powers the active transport of ions to mediate cellular transport. For example, it is needed for nerve-signal transmission through a sodium-potassium (Na⁺/K⁺) pump that relies on ATP to move ions against their concentration gradient, maintaining homeostasis¹⁶. Neurons exhibit a resting membrane potential of approximately −70 mV, primarily due to the uneven distribution of ions across the plasma membrane. The Na⁺/K⁺ ATPase actively transports three sodium ions out of the neuron and two potassium ions into the neuron against their concentration gradients, consuming ATP in the process. Furthermore, there is a rapid influx of sodium, leading to the restoration of membrane potential. This restoration is essential for the neuron’s readiness to fire subsequent action potentials, ensuring proper nerve-signal transmission.
• Muscle contraction: Muscle fibers require ATP during both contraction and relaxation phases¹⁷. During muscle contraction, ATP powers the interaction between actin and myosin. ATP hydrolysis provides energy for myosin heads to bind, perform the power stroke, and detach, enabling repeated contractions. In the skeletal muscles, ATP binds to the myosin head, causing it to detach from the actin filament. The hydrolysis of ATP to ADP and Pi then provides the energy for the myosin head to return to its original position, ready to bind to actin again and continue the contraction cycle.
• Cellular signaling: ATP serves as a substrate for kinases in phosphorylation reactions, which are fundamental in signal-transduction pathways¹⁸. These pathways regulate key cellular processes, such as growth, differentiation, and apoptosis. For instance, in the insulin signaling pathway, ATP is utilized by protein kinase B (PKB) to phosphorylate and inactivate glycogen synthase kinase 3 (GSK-3), promoting glycogen synthesis. This demonstrates how ATP-dependent phosphorylation regulates metabolic processes. In addition, different antibodies such as Anti-OXSR1 (phospho T185) antibody can trigger a cascade of kinase activities, influencing processes such as ion transport, blood pressure regulation, and responses to hypertonic stress.

Clinical relevance of oxidative phosphorylation

Mitochondrial dysfunction is implicated in a variety of diseases¹⁹. Understanding the molecular mechanism underlying OXPHOS is crucial for developing therapies aimed at restoring mitochondrial function.

Mitochondrial dysfunction and diseases

Mitochondrial OXPHOS uncouplers such as FCCP (ab120081) and CCCP (ab141229) disrupt the coupling between the ETC and ATP synthesis, leading to energy release in the form of heat rather than ATP²⁰. This uncoupling mechanism impairs mitochondrial energy production, thereby contributing to mitochondrial dysfunction.

Such dysfunction is linked to a range of diseases, including cardiovascular disorders, neurodegeneration, metabolic syndrome, and cancer²¹. Despite these challenges, mitochondria remain critical therapeutic targets, with emerging strategies focusing on mitochondrial replenishment and the targeting of mitochondrial components, showing promise in both clinical and preclinical trials. Potential therapeutic approaches include the use of mitochondrial DNA (mtDNA), mitochondria-specific microRNAs, and primary antibodies to enhance mitochondrial function in immunometabolic diseases and tissue injuries.

• Mutations in mitochondrial DNA (mtDNA) can lead to defects in OXPHOS, contributing to various human diseases²². One notable example is Leber’s hereditary optic neuropathy (LHON), a maternally inherited neurodegenerative disorder that causes optic nerve atrophy and primarily affects young adults, leading to blindness.
• The mitochondrial network plays a crucial role in integrating nutrient supply with cellular energy demands¹⁹. However, excessive nutrient supply, as seen in obesity, can lead to mitochondrial dysfunction. Mitochondrial fusion enhances oxidative capacity and ATP production, while fission is associated with metabolic stress, promoting mitochondrial fragmentation and oxidative stress. Mitochondria-derived ROS, particularly from Complex III, may play a pivotal role in adipogenesis, linking mitochondrial function to obesity-related diseases.
• Mutations in key mitochondrial enzymes are implicated in cancer progression, making mitochondrial metabolism a critical factor in tumor development¹⁹. For example, peroxisome proliferator-activated receptor gamma coactivator 1-alpha (PGC1-α), a key promoter of mitochondrial biogenesis, acts as a tumor suppressor. However, its levels are reduced under the influence of hypoxia-inducible factor 1-alpha (HIF-1α), which in turn stimulates glycolysis in cancer cells. Despite this shift towards glycolysis, mitochondria retain their biosynthetic functions, supplying metabolic intermediates necessary for cell proliferation and tumor growth.

Role in oxidative stress and aging

Aging is a complex biological process influenced by both genetic and environmental factors, with mitochondrial dysfunction playing a central role. This dysfunction affects several key cellular processes, including²³:

• Cellular energy production
• Oxidative balance
• Calcium (Ca²⁺) regulation

Disruptions in mitochondrial integrity, often caused by oxidative stress and calcium overload, lead to the production of free radicals, mutations in mtDNA, and cellular dysfunction. Mitochondrial dysfunction is strongly associated with age-related diseases, making it a primary target for potential anti-aging therapies.

For example, mitochondrial Ca²⁺ uptake plays a crucial role in breast cancer progression, particularly in aggressive triple-negative breast cancer, where it supports tumor growth and metastasis. Elevated mitochondrial Ca²⁺ promotes mitochondrial ROS (mROS) production, activating HIF-1α and sustaining high TCA cycle activity, which aids in cancer cell proliferation.

Aging increases the risk of numerous age-related diseases, including cardiovascular conditions such as atherosclerosis, hypertension, and heart disease. It is also linked to conditions such as diabetes, arthritis, cataracts, hearing loss, immune decline, and cancer. As individuals age, the risk of neurodegenerative diseases such as Alzheimer’s disease and Parkinson’s disease increases.

Applications in medicine

Given its central role in cellular energy production, the principles of OXPHOS and its potential dysregulation have significant applications in various fields of medicine:

• Certain cancer cells, particularly cancer stem cells and those resistant to chemotherapy, show increased reliance on OXPHOS for survival²⁴. This metabolic dependency presents a therapeutic target. Inhibiting OXPHOS can selectively eliminate these resilient cancer cell populations. Drugs such as metformin and atovaquone, traditionally used for non-oncologic conditions, have shown potential as OXPHOS inhibitors in cancer treatment.
• Some cancer cells exhibit an OXPHOS phenotype driven by specific genetic mutations. In non-small cell lung cancer (NSCLC) tumors with oncogenic KRAS mutations and LKB1 loss, complex I inhibitors such as phenformin selectively reduce oxygen consumption²⁵. These tumors struggle to compensate by upregulating glycolysis, making them particularly vulnerable to OXPHOS inhibition.
• In certain cases, nuclear-encoded versions of mitochondrial genes produce proteins that are imported into mitochondria to compensate for defects in mitochondrial DNA (mtDNA)-encoded proteins. This strategy, known as allotopic expression, has been investigated as a therapeutic approach for disorders such as Leber’s Hereditary Optic Neuropathy (LHON). Specifically, allotopic expression of the ND4 subunit of Complex I has progressed into clinical trials as a potential treatment²⁶.
• Defects in OXPHOS complexes are central to many mitochondrial disorders²⁷. Measuring OXPHOS activity in patient tissues helps diagnose conditions such as mitochondrial myopathies, Leigh syndrome, and MELAS.
• Impaired OXPHOS function is implicated in neurodegenerative diseases such as Parkinson’s, Alzheimer’s, and Huntington’s²⁸. Understanding mitochondrial dysfunction helps identify therapeutic targets and biomarkers.
• The heart’s high energy demands make it sensitive to OXPHOS dysfunction²⁹. Mitochondrial-targeted therapies are being explored to restore energy balance in failing hearts.
• OXPHOS efficiency influences insulin sensitivity in muscle and adipose tissue. Mitochondrial dysfunction is associated with type 2 diabetes, and modulating OXPHOS is an emerging strategy for improving metabolic health³⁰.
• In severe infections, mitochondrial OXPHOS can be impaired, contributing to organ failure³¹. Strategies to preserve or restore mitochondrial function are being evaluated in intensive care medicine.
• Diseases such as Barth syndrome and mitochondrial complex deficiencies are caused by mutations affecting OXPHOS³². Understanding these pathways enables more precise metabolic management and genetic counseling.

Inhibitors of oxidative phosphorylation

Some OXPHOS inhibitors, used in research and clinical settings are listed below^{33, 34}.

Evolutionary and comparative insights

Mitochondria are believed to have originated from a prokaryote with OXPHOS, which was integrated into a eukaryotic cell over 1.45 billion years ago¹⁰. This development allowed for the efficient ATP production necessary to support larger genomes, cellular specialization, and energy-demanding processes, enabling the evolution of complex life forms, including higher-order plants and animals.

In animals, OXPHOS serves as the primary ATP source for biosynthesis, ion balance, and mechanical work such as locomotion, while in plants, it provides energy when photosynthesis is unavailable.

Its universal presence in higher-order life forms highlights its crucial role in evolution, making its study essential for understanding metabolism and the conditions that led to complex life on Earth.

Comparison of oxidative phosphorylation in mitochondria to ATP synthesis in chloroplasts during photosynthesis.

Mitochondria and chloroplasts are both membrane-bound organelles responsible for ATP production in eukaryotic cells. Although mitochondria are present in nearly all eukaryotic organisms, chloroplasts are found only in plants. The processes of OXPHOS and photophosphorylation are similar in that they both rely on extensive internal membranes to support electron transport and energy conversion. The differences between OXPHOS and photophosphorylation are listed below⁴:

Differences between substrate-level phosphorylation and oxidative phosphorylation

In contrast to the electron transport-driven ATP synthesis of OXPHOS, substrate-level phosphorylation represents a more direct mechanism^{38, 39}. The following table highlights the key distinctions between these two fundamental ATP-generating processes.

FAQs

How does the electron transport chain contribute to ATP synthesis?

The electron transport chain transfers electrons through a series of complexes, pumping protons across the inner mitochondrial membrane to establish a proton gradient. This proton gradient powers ATP synthase, allowing it to convert ADP into ATP as protons flow back into the mitochondrial matrix. Consequently, the ETC effectively couples redox reactions to ATP synthesis, making it essential for cellular energy production.

What role does the proton gradient play in oxidative phosphorylation?

The proton gradient, formed by the electron transport chain, creates an electrochemical potential across the inner mitochondrial membrane. This gradient drives protons back into the mitochondrial matrix through ATP synthase, powering the production of ATP. Therefore, the proton gradient is essential in coupling electron transport with ATP synthesis, ensuring efficient energy production.

How many ATP molecules are produced during oxidative phosphorylation?
Approximately 34 ATP molecules are produced from oxidative phosphorylation per glucose molecule, contributing to the total of about 38 ATP molecules generated during cellular respiration.

How do poisons such as cyanide affect oxidative phosphorylation?

Cyanide, a potent inhibitor of oxidative phosphorylation, binds irreversibly to cytochrome c oxidase (Complex IV) of the electron transport chain in mitochondria. This prevents the transfer of electrons to oxygen, the final electron acceptor. As a result, electron flow stops, disrupting the proton gradient across the inner mitochondrial membrane. ATP production ceases since ATP synthase relies on the proton gradient for function. Cellular respiration shuts down, leading to energy failure and potentially cell death, especially in high-energy-demand tissues such as the brain and heart. Therefore, cyanide poisoning is lethal without prompt treatment, owing to the rapid shutdown of ATP production.

How does oxidative phosphorylation tie into overall cellular respiration?

Oxidative phosphorylation is the energy payoff phase of cellular respiration, converting the energy stored in electron carriers (NADH and FADH₂) into usable ATP. Without it, cells would rely on much less efficient processes such as glycolysis alone.

Conclusion

OXPHOS integrates biochemistry, thermodynamics, and cellular architecture to enable efficient ATP production, essential for sustaining life across diverse organisms. This highly regulated process, involving electron transfer through multi-subunit complexes in the ETC, ultimately results in the reduction of molecular oxygen to water. The proton gradient and membrane potential generated through this process provide the energy needed for ATP synthesis by ATP synthase.

Dysfunction in oxidative phosphorylation is increasingly recognized as a key factor in the development of metabolic disorders, neurodegenerative diseases, and aging. As advancements in structural biology and bioenergetics continue, OXPHOS remains a focal point for future therapeutic innovations, offering promising avenues for the treatment of a wide range of diseases.

References

1. Chaban, Y., Boekema, E. J., & Dudkina, N. V. Structures of mitochondrial oxidative phosphorylation supercomplexes and mechanisms for their stabilisation. Biochimica et Biophysica Acta (BBA)-Bioenergetics, 1837, 418-426 (2014).

2. Mitchell, P. Chemiosmotic coupling in oxidative and photosynthetic phosphorylation. Biochimica et Biophysica Acta (BBA)-Bioenergetics, 1807, 1507-1538 (2011).

3. Meyer, E. H., Letts, J. A., & Maldonado, M. Structural insights into the assembly and the function of the plant oxidative phosphorylation system. New Phytologist, 235, 1315-1329 (2022).

4. Alberts B, Johnson A, Lewis J, et al. Energy Conversion: Mitochondria and Chloroplasts. In Molecular Biology of the Cell. 4th edition. Garland Science (2002)

5. Cooper GM. The Mechanism of Oxidative Phosphorylation. In The Cell: A Molecular Approach. 2nd edition. Sunderland (MA): Sinauer Associates (2000)

6. Neupane, P., Bhuju, S., Thapa, N., et al. ATP synthase: structure, function and inhibition. Biomolecular concepts, 10, 1-10 (2019).

7. Deshpande, O. A., & Mohiuddin, S. S. Biochemistry, oxidative phosphorylation. In StatPearls [Internet]. StatPearls Publishing (2023).

8. Dawson J. F. The Overall Efficiency of Oxidative Phosphorylation. In BIOC*2580 Introduction to Biochemistry. University of Guelph. Pressbooks (2021)

9. Tomar, N., Zhang, X., Kandel, S. M., et al. Substrate-dependent differential regulation of mitochondrial bioenergetics in the heart and kidney cortex and outer medulla. Biochimica et Biophysica Acta (BBA)-Bioenergetics, 1863, 148518 (2022).

10. Wilson, D. F. Oxidative phosphorylation: regulation and role in cellular and tissue metabolism. The Journal of physiology, 595, 7023-7038 (2017).

11. Kadenbach, B. Regulation of cytochrome c oxidase contributes to health and optimal life. World Journal of Biological Chemistry, 11, 52 (2020).

12. Wheaton, W. W., & Chandel, N. S. Hypoxia. 2. Hypoxia regulates cellular metabolism. American Journal of Physiology-Cell Physiology, 300, C385-C393 (2011).

13. Morin, C., Zini, R., Simon, N., et al. Low glucocorticoid concentrations decrease oxidative phosphorylation of isolated rat brain mitochondria: an additional effect of dexamethasone. Fundamental & clinical pharmacology, 14, 493-500 (2000).

14. San-Millán, I., & Brooks, G. A. Reexamining cancer metabolism: lactate production for carcinogenesis could be the purpose and explanation of the Warburg Effect. Carcinogenesis, 38, 119-133 (2017).

15. du Plessis, S. S., Agarwal, A., Mohanty, G., et al. Oxidative phosphorylation versus glycolysis: what fuel do spermatozoa use? Asian journal of andrology, 17, 230-235 (2015).

16. Pirahanchi, Y., Jessu, R., & Aeddula, N. R. Physiology, sodium potassium pump. In StatPearls [Internet]. StatPearls Publishing (2023).

17. Gash, M. C., Kandle, P. F., Murray, I. V., et al. Physiology, muscle contraction. In StatPearls [Internet]. StatPearls Publishing (2023).

18. Ardito, F., Giuliani, M., Perrone, D., et al. The crucial role of protein phosphorylation in cell signaling and its use as targeted therapy. International journal of molecular medicine, 40, 271-280 (2017).

19. Diaz-Vegas, A., Sanchez-Aguilera, P., Krycer, J. R., et al. Is mitochondrial dysfunction a common root of noncommunicable chronic diseases?. Endocrine reviews, 41, bnaa005 (2020).

20. Song, Y., & Villeneuve, D. L. AOP report: uncoupling of oxidative phosphorylation leading to growth inhibition via decreased cell proliferation. Environmental toxicology and chemistry, 40, 2959-2967 (2021).

21. Zong, Y., Li, H., Liao, P., et al. Mitochondrial dysfunction: mechanisms and advances in therapy. Signal transduction and targeted therapy, 9, 124 (2024).

22. Al‐Kafaji, G., Alharbi, M. A., Alkandari, H., et al. Analysis of the entire mitochondrial genome reveals Leber’s hereditary optic neuropathy mitochondrial DNA mutations in an Arab cohort with multiple sclerosis. Scientific Reports, 12, 11099 (2022).

23. Somasundaram, I., Jain, S. M., Blot-Chabaud, M., et al. Mitochondrial dysfunction and its association with age-related disorders. Frontiers in Physiology, 15, 1384966 (2024).

24. Ashton, T. M., McKenna, W. G., Kunz-Schughart, L. A., et al. Oxidative phosphorylation as an emerging target in cancer therapy. Clinical Cancer Research, 24, 2482-2490 (2018).

25. Xu, Y., Xue, D., Bankhead III, A., et al. Why all the fuss about oxidative phosphorylation (OXPHOS)?. Journal of medicinal chemistry, 63, 14276-14307 (2020).

26. Cwerman-Thibault, H., Augustin, S., Lechauve, C., et al. Nuclear expression of mitochondrial ND4 leads to the protein assembling in complex I and prevents optic atrophy and visual loss. Molecular Therapy Methods & Clinical Development, 2, 15003 (2015).

27. Fernandez‐Vizarra, E., & Zeviani, M. Mitochondrial disorders of the OXPHOS system. FEBS letters, 595, 1062-1106 (2021).

28. Kawamata, H., & Manfredi, G. Proteinopathies and OXPHOS dysfunction in neurodegenerative diseases. Journal of Cell Biology, 216, 3917-3929 (2017).

29. Elorza, A. A., & Soffia, J. P. mtDNA heteroplasmy at the core of aging-associated heart failure. An integrative view of OXPHOS and mitochondrial life cycle in cardiac mitochondrial physiology. Frontiers in Cell and Developmental Biology, 9, 625020 (2021).

30. Prasun, P. Role of mitochondria in pathogenesis of type 2 diabetes mellitus. Journal of Diabetes & Metabolic Disorders, 19, 2017-2022 (2020).

31. Nedel, W., Deutschendorf, C., & Portela, L. V. C. Sepsis-induced mitochondrial dysfunction: A narrative review. World Journal of Critical Care Medicine, 12, 139 (2023).

32. Ikon, N., & Ryan, R. O. Barth syndrome: connecting cardiolipin to cardiomyopathy. Lipids, 52, 99-108 (2017).

33. Miranda, M., Christofk, H., Jones, D. L., et al. Topical inhibition of the electron transport chain can stimulate the hair cycle. Journal of Investigative Dermatology, 138, 968-972 (2018).

34. Ye, J., Jiang, Z., Chen, X., et al. Electron transport chain inhibitors induce microglia activation through enhancing mitochondrial reactive oxygen species production. Experimental cell research, 340, 315-326 (2016).

35. Ayajuddin, M., Phom, L., Koza, Z., et al. Adult health and transition stage-specific rotenone-mediated Drosophila model of Parkinson’s disease: Impact on late-onset neurodegenerative disease models. Frontiers in molecular neuroscience, 15, 896183 (2022).

36. Han, S. Y., Jeong, Y. J., Choi, Y., et al. Mitochondrial dysfunction induces the invasive phenotype, and cell migration and invasion, through the induction of AKT and AMPK pathways in lung cancer cells. International journal of molecular medicine, 42, 1644-1652 (2018).

37. Abdrakhmanov, A., Yapryntseva, M. A., Kaminskyy, V. O., et al. Receptor-mediated mitophagy rescues cancer cells under hypoxic conditions. Cancers, 13, 4027 (2021).

38. Hunt, K. A., Flynn, J. M., Naranjo, B., et al. Substrate-level phosphorylation is the primary source of energy conservation during anaerobic respiration of Shewanella oneidensis strain MR-1. Journal of bacteriology, 192, 3345-3351 (2010).

39. Aminuddin, M. Substrate level versus oxidative phosphorylation in the generation of ATP in Thiobacillus denitrificans. Archives of microbiology, 128, 19-25 (1980).